Abraxis Oncology Names Joseph Hogan Vice President of U.S. Sales and Marketing.SCHAUMBURG, Ill. -- American BioScience Inc. and American Pharmaceutical Partners, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :APPX APPX Appendix APPX Application eXcellence (4GL software development tool) ) today announced the appointment of Joseph Hogan to the new position of vice president of U.S. sales and marketing for Abraxis(TM) Oncology. Hogan will be responsible for leading the U.S. sales and marketing teams for ABRAXANE(R) for Injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. Suspension (paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); protein-bound particles for injectable suspension) (albumin-bound) and will be reporting to Barry Flannelly, Pharm.D, global vice president of sales and marketing. At the close of the merger between American Pharmaceutical Partners (APP See application. app - application program ) and American BioScience (ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ) in the second quarter of this year, Abraxis Oncology will become a division of Abraxis BioScience, a fully integrated global biopharmaceutical company. "We are fortunate to have Joe join the Abraxis Oncology team. His experience and deep understanding of the needs of cancer patients will be invaluable as we work toward transforming the way cancer is treated," said Flannelly. "Joe will play a critical role in the expansion of our U.S. sales and marketing activities that will help physicians and patients to better understand the benefits of next generation cancer therapies." Mr. Hogan brings to Abraxis Oncology extensive expertise in sales, marketing and global brand development in the oncology field. Hogan was most recently head of global oncology marketing for Berlex. Prior to joining Berlex, he served in numerous leadership positions at Sanofi-Aventis, including that of U.S. marketing director for Taxotere(R) where he played a key role in developing brand strategy for the product in breast, lung and prostate cancers prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . About American BioScience, Inc. American BioScience, Inc. is a privately held biotechnology company focused on the discovery, development and delivery of next-generation therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. including biologically active molecules already existing within the human biological system, for the treatment of life-threatening diseases. ABI owns a majority interest in American Pharmaceutical Partners, Inc. About American Pharmaceutical Partners, Inc. American Pharmaceutical Partners, Inc. is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. Abraxis(TM) Oncology, the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). For more information, visit APP's website at www.appdrugs.com and www.abraxisoncology.com. Taxotere(R) is a registered trademark of Aventis Pharmaceuticals, Inc. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion